RSS

Cambrex

Small molecule company Cambrex is to be acquired by investment firm Permira for approximately $2.4 billion, the company has announced. Read more

News

Small molecule company Cambrex has announced an expansion of its solid form screening and crystallisation process development facility in Edinburgh, Scotland. Read more

News

Dr Anthony Qu, vice president of scientific affairs at Cambrex and Dr Yanjun Zhao, market intelligence manager examine the complexities of developing oral doses for the paediatric market. Read more

, Opinion

Small molecule company Cambrex has opened a new quality control (QC) laboratory at its site in Paullo, Milan, Italy. Read more

News

Small molecule company Cambrex has completed the expansion of a new research and development facility in Italy. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has completed its acquisition of dosage form contract development and manufacturing organisation (CDMO), Halo Pharma. Read more

News

Manufacturer of small molecule innovator and generic APIs, Cambrex, has entered into a definitive agreement to acquire Halo Pharma — a dosage form contract development and manufacturing organisation (CDMO). Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has announced that it will expand research and development capabilities at its Milan site. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has started a $5 million expansion of laboratory facilities at its Karlskoga site in Sweden. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has announced the completion of its pilot plant expansion at its High Point facility in North Carolina. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has revealed that it will be investing in the expansion of chemical and analytical development capabilities at its Charles City, Iowa plant Read more

News

A ceremony has been held in Sweden marking the start of a long-term manufacturing agreement between Cambrex — manufacturer of small molecule innovator and active pharmaceutical ingredients — and AstraZeneca. Read more

News

Simon Edwards, VP, Global Sales and Business Development, Cambrex, tells us about their opportunities and challenges of the year. Read more

Opinion

With the industry experiencing dramatic change, from regulatory changes to investments in capacity and the uncertainty of the political landscape, we asked several industry heads to review the opportunities, challenges and trends of 2017. Read more

Opinion

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has completed an expansion of cGMP small scale capacity at its Charles City plant in Iowa. Read more

News

The organisers of CPhI Worldwide have revealed the winners of the 14th Pharma Awards. Read more

News

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex has installed a new, large scale manufacturing capacity at its cGMP facility in Karlskoga, Sweden. Read more

News

Manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), Cambrex, is expanding its High Point, North Carolina facility with the addition of a new $3.2 million, 11,000 sq ft analytical laboratory. Read more

Technology

Cambrex, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), is investing $24 million in a new highly potent API manufacturing facility in Charles City, Iowa. Read more

News

Jonathan Knight, VP New Product Development at Cambrex, dissects the route used to manufacture APIs, highlighting those steps that can make a process ideal. Read more

Opinion